RxDoctor Payments Data

Tom Raetzsch, MD

Family Medicine · Seguin, TXNPI 1629156765

Payments from drug & device makers

$2,090in general payments, 2019–2025

Across 80 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amarin Pharma, Inc.$345
  • Novo Nordisk$121
  • Nevro Corp.$84
  • Amgen$83
  • GSK$69
  • plus $244 from 10 others

What the payments were for

  • Food & beverage$2,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,090 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$106,554
Medicare patients
333
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol138$96,911
OzempicSemaglutide62$82,665
JardianceEmpagliflozin55$53,258
TradjentaLinagliptin82$43,898
EliquisApixaban34$29,331
MounjaroTirzepatide18$18,484
MyrbetriqMirabegron15$10,425
JanuviaSitagliptin Phosphate18$7,500
Tresiba Flextouch U-100Insulin Degludec12$6,637
SynthroidLevothyroxine Sodium94$6,456
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,316
Atorvastatin Calcium533$4,025
Dexlansoprazole DrDexlansoprazole19$3,689
Levothyroxine Sodium420$3,290
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,143$96,911138 claims
Novo NordiskOzempic$121$82,66562 claims
PfizerEliquis$38$29,33134 claims
Lilly USA, LLCMounjaro$56$18,48418 claims
MerckJanuvia, Lagevrio (Eua)$13$8,49531 claims
GSKAnoro Ellipta$69$5,31612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →